Floatz logo

16 assets in Ureter Cancer

Therapeutic assets addressing Ureter Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Ureter Cancer
Fred Hutchinson Cancer CenterP2BB (65)
Pembrolizumab
Ureter Cancer
Fred Hutchinson Cancer CenterP2BB (64)
Lidocaine
Ureter Cancer
Hans BahlmannP3B (60)
Marcaine
Ureter Cancer
Hans BahlmannP3B (60)
Nepenthe
Ureter Cancer
Hans BahlmannP3B (60)
Nivolumab
Ureter Cancer
M.D. Anderson Cancer CenterP2B (60)
Ipilimumab
Ureter Cancer
M.D. Anderson Cancer CenterP2B (59)
Atezolizumab
Ureter Cancer
National Cancer Institute (NCI)P2B (57)
Apsolol
Ureter Cancer
Emory UniversityP2CCC (53)
Eribulin Monomethanesulfonate
Ureter Cancer
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Ureter Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Tocilizumab
Ureter Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Avelumab
Ureter Cancer
Emory UniversityP2CCC (48)
Quemliclustat
Ureter Cancer
Fred Hutchinson Cancer CenterP1/2CC (47)
Cabozantinib
Ureter Cancer
National Cancer Institute (NCI)P1CC (43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Ureter Cancer
National Cancer Institute (NCI)P1CC (43)